Reshaping the TME to enhance checkpoint blockade in ENKTL
- PMID: 40638203
- DOI: 10.1182/blood.2025028917
Reshaping the TME to enhance checkpoint blockade in ENKTL
Comment on
-
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.Blood. 2025 Jul 10;146(2):155-166. doi: 10.1182/blood.2024027109. Blood. 2025. PMID: 40073374 Clinical Trial.